PF-Atlas › Clinical Trials › ISABELA-1/2
Ziritaxestat Autotaxin/LPA Inhibitor in IPF — FAILED
Ziritaxestat · Autotaxin/LPA1 · Phase 3
Registry ID
ISABELA-1/2
Phase
Phase 3
Status
Completed
Drug / intervention
Ziritaxestat
Mechanism
Autotaxin/LPA1
Sponsor
Galapagos
Start
2019-06
About this trial
Ziritaxestat is evaluated in ISABELA-1/2, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Galapagos, targeting autotaxin/lpa1. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for ISABELA-1/2 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.